|
1
|
Yin YF, Jia QY, Yao HF, Zhu YH, Zheng JH, Duan ZH, Hu CY, Sun YW, Liu DJ, Huo YM, Liu W. OCIAD2 promotes pancreatic cancer progression through the AKT signaling pathway. Gene 2024:148735. [PMID: 38944166 DOI: 10.1016/j.gene.2024.148735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2023] [Revised: 05/18/2024] [Accepted: 06/11/2024] [Indexed: 07/01/2024]
Abstract
BACKGROUND OCIAD2（Ovarian carcinoma immunoreactive antigen-like protein 2） is a protein reported in various cancers. However, the role of OCIAD2 has not been explored in pan-cancer datasets. The purpose of this research lies in analyzing the expression level and prognostic-related value of OCIAD2 in different human cancers, as well as revealing the underlying mechanism in specific cancer type (pancreatic adenocarcinoma, PAAD). METHODS The correlation between OCIAD2 expression level and clinical relevance in different human cancers was investigated from bioinformatical perspective (GTEx and TCGA). The OCIAD2 expression level and clinical significance in PAAD were explored in GEO datasets and tissue microarray. Functional experiments were used to determine the OCIAD2 cell functions in vitro and in vivo. GSEA, western blot and immunohistochemistry were used to uncover the potential mechanism. RESULTS OCIAD2 expression level was closely correlated with clinical relevance in many cancer types through pan-cancer analysis, and we found OCIAD2 was highly expressed in PAAD and associated with poorer prognosis. OCIAD2 acted as the promotor of Warburg effect and influenced PAAD cells proliferation, migration and apoptosis. Mechanistically, OCIAD2 upregulation may boost glycolysis in PAAD via activating the AKT signaling pathway in PAAD. CONCLUSIONS In PAAD, OCIAD2 promotes Warburg effect via AKT signaling pathway and targeting cancer cells metabolic reprogramming could be a potential treatment.
Collapse
Affiliation(s)
- Yi-Fan Yin
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China
| | - Qin-Yuan Jia
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China
| | - Hong-Fei Yao
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China
| | - Yu-Heng Zhu
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China
| | - Jia-Hao Zheng
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China
| | - Zong-Hao Duan
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China
| | - Cheng-Yu Hu
- Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China
| | - Yong-Wei Sun
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China
| | - De-Jun Liu
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China.
| | - Yan-Miao Huo
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China.
| | - Wei Liu
- State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200240, PR China; Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai 200127, PR China.
| |
Collapse
|
|
2
|
Feng T, Li M, Zhang L, Li S, Yang Z, Kang L, Guo Y, Kong L, Wang T. Immunity of two novel hepatitis C virus polyepitope vaccines. Vaccine 2022; 40:6277-6287. [PMID: 36150975 DOI: 10.1016/j.vaccine.2022.09.020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2022] [Revised: 08/01/2022] [Accepted: 09/05/2022] [Indexed: 11/17/2022]
Abstract
Hepatitis C virus (HCV) infection remains a serious public health burden around the world. So far there is no effective vaccine against this virus. Neutralizing antibody (NAb) responses to the epitopes within HCV E1 and E2 proteins are related to the resolution of hepatitis C infection. E. coli heat-labile enterotoxin B subunit (LTB) has been described as potent immunity adjuvants. In this study, we constructed recombinant pET vectors: pET-R9-Bp (B cell polyepitopes) expressing 7 epitopes from HCV E1 and E2 proteins including R9 (E2384-411aa)-Bp (E1313-327aa-E2396-424aa-E2436-447aa-E2523-540aa-E2610-627aa-E2631-648aa) and pET-LTB-R9-Bp expressing LTB adjuvant in combination with R9-Bp. Recombinant proteins R9-Bp and LTB-R9-Bp were expressed successfully in E. coli and purified by the Ni-NTA column. Both R9-Bp and LTB-R9-Bp in BALB/c mice induced robust humoral immune response in the context of intraperitoneal or intramuscular immunization but not oral immunization. Intraperitoneal administration of LTB-R9-Bp induced a higher antibody titer (peak titer: 1:341000) than that of R9-Bp (peak titer: 1:85000) after the second boost (P = 0.0036 or 0.0002). However, comparable antibody peak titers were elicited for both R9-Bp and LTB-R9-Bp in intramuscular immunization albeit with significant difference (P = 0.0032) a week after the second boost. In addition, both R9-Bp and LTB-R9-Bp induced the secretion of cytokines including IFN-γ and IL-4 at similar levels. anti-sera induced by both R9-Bp and LTB-R9-Bp recognized native HCV E1 and E2 proteins. Moreover, these HCV-specific antisera inhibited significantly the entry of HCV (P < 0.0001). Taken together, these findings showed that E. coli-based both R9-Bp and LTB-R9-Bp could become promising HCV vaccines.
Collapse
Affiliation(s)
- Tian Feng
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China
| | - Mingzhi Li
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China
| | - Lirong Zhang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China
| | - Sha Li
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China
| | - Zibing Yang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China
| | - Lumei Kang
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, Jiangxi, China; Center for Laboratory Animal Science, Nanchang University, Nanchang, Jiangxi, China
| | - Yunli Guo
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China
| | - Lingbao Kong
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China.
| | - Ting Wang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Nanchang, Jiangxi, China; Institute of Pathogenic Microorganism, Jiangxi Agricultural University, Nanchang, Jiangxi, China; College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, Jiangxi, China.
| |
Collapse
|
|
3
|
Li M, Weng S, Wang Q, Yang Z, Wang X, Yin Y, Zhou Q, Zhang L, Tao F, Li Y, Jia M, Yang L, Xin X, Li H, Kang L, Wang Y, Wang T, Li S, Kong L. Reduced binding activity of vaccine serum to omicron receptor-binding domain. Front Immunol 2022; 13:960195. [PMID: 35967350 PMCID: PMC9369000 DOI: 10.3389/fimmu.2022.960195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2022] [Accepted: 06/28/2022] [Indexed: 11/13/2022] Open
Abstract
Coronavirus disease 2019 (COVID-19) vaccination regimens contribute to limiting the spread of severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2). However, the emergence and rapid transmission of the SARS-CoV-2 variant Omicron raise a concern about the efficacy of the current vaccination strategy. Here, we expressed monomeric and dimeric receptor-binding domains (RBDs) of the spike protein of prototype SARS-CoV-2 and Omicron variant in E. coli and investigated the reactivity of anti-sera from Chinese subjects immunized with SARS-CoV-2 vaccines to these recombinant RBDs. In 106 human blood samples collected from 91 participants from Jiangxi, China, 26 sera were identified to be positive for SARS-CoV-2 spike protein antibodies by lateral flow dipstick (LFD) assays, which were enriched in the ones collected from day 7 to 1 month post-boost (87.0%) compared to those harvested within 1 week post-boost (23.8%) (P < 0.0001). A higher positive ratio was observed in the child group (40.8%) than adults (13.6%) (P = 0.0073). ELISA results showed that the binding activity of anti-SARS-CoV-2 antibody-positive sera to Omicron RBDs dropped by 1.48- to 2.07-fold compared to its homogeneous recombinant RBDs. Thus, our data indicate that current SARS-CoV-2 vaccines provide restricted humoral protection against the Omicron variant.
Collapse
Affiliation(s)
- Mingzhi Li
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Shiqi Weng
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Quansheng Wang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Zibing Yang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Xiaoling Wang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
- GMU-GIBH Joint School of Life Sciences, Guangzhou Medical University, Guangzhou, China
| | - Yanjun Yin
- Department of Clinical Laboratory, Jiangxi Provincial Children’s Hospital, Nanchang, China
| | - Qiuxiang Zhou
- Department of Clinical Laboratory, The Affiliated Hospital of Jiangxi Agricultural University, Nanchang, China
| | - Lirong Zhang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Feifei Tao
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Yihan Li
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Mengle Jia
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Lingdi Yang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Xiu Xin
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Hanguang Li
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
| | - Lumei Kang
- College of Animal Science and Technology, Jiangxi Agricultural University, Nanchang, China
- Center for Laboratory Animal Science, Nanchang University, Nanchang, China
| | - Yu Wang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
- *Correspondence: Yu Wang, ; Ting Wang, ; Sha Li, ; Lingbao Kong,
| | - Ting Wang
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
- *Correspondence: Yu Wang, ; Ting Wang, ; Sha Li, ; Lingbao Kong,
| | - Sha Li
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
- *Correspondence: Yu Wang, ; Ting Wang, ; Sha Li, ; Lingbao Kong,
| | - Lingbao Kong
- Nanchang City Key Laboratory of Animal Virus and Genetic Engineering, Institute of Pathogenic Microorganism, College of Bioscience and Engineering, Jiangxi Agricultural University, Nanchang, China
- *Correspondence: Yu Wang, ; Ting Wang, ; Sha Li, ; Lingbao Kong,
| |
Collapse
|